Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 3, 2007, Pages 439-453

  Zenz, Thorsten ^a   Döhner, Hartmut ^a   Stilgenbauer, Stephan ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

17p deletion; CLL; genetics; p53

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CELL MARKER; CHLORAMBUCIL; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; MOLECULAR MARKER; PURINE DERIVATIVE; RITUXIMAB; STEROID;

ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GENETICS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC DISORDER; GENOMICS; HUMAN; LYMPHADENOPATHY; MEDICAL DECISION MAKING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TRISOMY 12; TUMOR SUPPRESSOR GENE;

CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 17; GENE DELETION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PROGNOSIS; RISK; SURVIVAL ANALYSIS; TRISOMY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34547863530     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.02.006     Document Type: Review

References (61)

1. Chiorazzi N., Rai K.R., and Ferrarini M. Chronic lymphocytic leukemia. The New England Journal of Medicine 352 (2005) 804-815
2. Rozman C., and Montserrat E. Chronic lymphocytic leukemia. The New England Journal of Medicine 333 (1995) 1052-1057
3. Zwiebel J.A., and Cheson B.D. Chronic lymphocytic leukemia: staging and prognostic factors. Seminars in Oncology 25 (1998) 42-59
4. Dighiero G., Maloum K., Desablens B., et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. The New England Journal of Medicine 338 (1998) 1506-1514
5. Binet J.L., Auquier A., Dighiero G., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48 (1981) 198-206
6. Rai K.R., Sawitsky A., Cronkite E.P., et al. Clinical staging of chronic lymphocytic leukemia. Blood 46 (1975) 219-234
7. Montserrat E., Sanchez-Bisono J., Vinolas N., and Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia: analysis of its prognostic significance. British Journal of Haematology 62 (1986) 567-575
8. Rozman C., Montserrat E., Rodriguez-Fernandez J.M., et al. Bone marrow histologic pattern-the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 64 (1984) 642-648
9. Di Giovanni S., Valentini G., Carducci P., and Giallonardo P. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematologica 81 (1989) 181-185
10. Hallek M., Langenmayer I., Nerl C., et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 93 (1999) 1732-1737
11. Kallander C.F., Simonsson B., Hagberg H., and Gronowitz J.S. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer 54 (1984) 2450-2455
12. Knauf W.U., Langenmayer I., Ehlers B., et al. Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leukemia & Lymphoma 27 (1997) 523-532
13. Krober A., Seiler T., Benner A., et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100 (2002) 1410-1416
14. Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. The New England Journal of Medicine 348 (2003) 1764-1775
15. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94 (1999) 1840-1847
16. Hamblin T.J., Davis Z., Gardiner A., et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 (1999) 1848-1854
17. Lin K., Sherrington P.D., Dennis M., et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 100 (2002) 1404-1409
18. Orchard J.A., Ibbotson R.E., Davis Z., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukemia. Lancet 363 (2004) 105-111
19. Oscier D.G., Gardiner A.C., Mould S.J., et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100 (2002) 1177-1184
20. Rassenti L.Z., Huynh L., Toy T.L., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. The New England Journal of Medicine 351 (2004) 893-901
21. Vasconcelos Y., Davi F., Levy V., et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. Journal of Clinical Oncology 21 (2003) 3928-3932
22. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. The New England Journal of Medicine 343 (2000) 1910-1916
23. Mertens D., Wolf S., Tschuch C., et al. Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism. Proceedings of the National Academy of Sciences of the United States of America 103 (2006) 7741-7746
24. Dohner H., Stilgenbauer S., James M.R., et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 89 (1997) 2516-2522
25. Dohner H., Fischer K., Bentz M., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85 (1995) 1580-1589
26. El Rouby S., Thomas A., Costin D., et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82 (1993) 3452-3459
27. Fenaux P., Preudhomme C., Lai J.L., et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 6 (1992) 246-250
28. Gaidano G., Ballerini P., Gong J.Z., et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America 88 (1991) 5413-5417
29. Kröber A., Scherer K., Leupolt E., et al. Evaluation of the p53 mutation and deletion status in B-CLL demonstrates resistance to therapy in vivo and confirms prognostic impact. Blood 96 (2000) (abstract)
30. Sturm I., Bosanquet A.G., Hermann S., et al. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death and Differentiation 10 (2003) 477-484
31. Trbusek M., Malcikova J., Smardova J., et al. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukemia 20 (2006) 1159-1161
32. Lens D., De Schouwer P.J., Hamoudi R.A., et al. p53 abnormalities in B-cell prolymphocytic leukemia. Blood 89 (1997) 2015-2023
33. Wattel E., Preudhomme C., Hecquet B., et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84 (1994) 3148-3157
34. Austen B., Powell J.E., Alvi A., et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 106 (2005) 3175-3182
35. Schaffner C., Stilgenbauer S., Rappold G.A., et al. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 94 (1999) 748-753
36. Stankovic T., Weber P., Stewart G., et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukemia. Lancet 353 (1999) 26-29
37. Bullrich F., Rasio D., Kitada S., et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Research 59 (1999) 24-27
38. Krober A., Bloehdorn J., Hafner S., et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. Journal of Clinical Oncology 20 24 (2006) 969-975
39. Rosenwald A., Alizadeh A.A., Widhopf G., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. The Journal of Experimental Medicine 194 (2001) 1639-1647
40. Binet J.L., Caligaris-Cappio F., Catovsky D., et al. International Workshop on Chronic Lymphocytic Leukemia (IWCLL). Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107 (2006) 859-861
41. Shanafelt T.D., Witzig T.E., Fink S.R., et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. Journal of Clinical Oncology 24 (2006) 4634-4641
42. Stilgenbauer S., Kröber A., Winkler D., et al. VH mutation status and genomic aberrations in the prospective CLL1 trial (Binet A) of the German CLL Study Group (GCLLSG). Blood 100 supplement 1 (2002) 168 (abstract #628)
43. Bergmann M., Eichhorst B., Busch R., and Hallek M. Elevated thymidine kinase and short lymphocyte doubling time in combination with unfavourable cytogenetics or unmutated IgVH status are strong predictors for high individual risk for rapid disease progression in patients with B-CLL in Binet A Stage: an interim report from the CLL1 Protokoll of the German CLL Study Group (GCLLSG). Blood 102 (2003) (abstract #2464)
44. Eichhorst B.F., Busch R., Hopfinger G., et al., German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107 (2006) 885-891
45. Deutsch Studiengruppe. http://dcllsg.de.
46. Geisler C.H., Philip P., Christensen B.E., et al. In B-cell chronic lymphocytic leukemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leukemia Research 21 (1997) 1011-1023
47. Byrd J.C., Gribben J.G., Peterson B.L., et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. Journal of Clinical Oncology 24 (2006) 437-443
48. Stilgenbauer S., and Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. The New England Journal of Medicine 347 (2002) 452-453
49. Lozanski G., Heerema N.A., Flinn I.W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103 (2004) 3278-3281
50. Pettitt A.R., Matutes E., and Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukemia patients with p53 defects. Leukemia 20 (2006) 1441-1445
51. http://www.clinicaltrials.gov/show/NCT00292760
52. Stilgenbauer S., Kröber A., Busch R., et al. 17p deletion predicts for inferior overall survival after fludarabine - based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 Trial of the GCLLSG. Blood 106 (2005) 715
53. Oscier D.G., Richards S., Orchard J., et al. Prognostic Factors in the UK LRF CLL4 Trial. Blood 106 (2005) 2099
54. Dreger P., and Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 16 (2002) 985-992
55. Zenz T., Ritgen M., Dreger P., et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 108 (2006) 2127-2130
56. Ritgen M., Lange A., Stilgenbauer S., et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 101 (2003) 2049-2053
57. Dreger P., Stilgenbauer S., Benner A., et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 103 (2004) 2850-2858
58. Ritgen M., Stilgenbauer S., von Neuhoff N., et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104 (2004) 2600-2602
59. Moreno C., Villamor N., Colomer D., et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 23 (2005) 3433-3438
60. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. Journal of Clinical Oncology 23 (2005) 3819-3829
61. Gribben J.G., Zahrieh D., Stephans K., et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106 (2005) 4389-4396